Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
case, compound, condensed, consecutive, criteria, decision, decitabine, doubt, enabling, endorse, enhance, float, free, greater, Instruction, met, morphologic, move, objective, pancreatic, penetrate, point, ratio, reserved, split, USPTO
Removed:
aberrant, aberrantly, abstract, accessible, accomplishment, account, accumulation, achieving, activated, active, actively, add, added, addressed, Administratively, advantage, advice, Agency, aggressive, aid, American, anthracycline, area, ASC, ASH, assay, assessed, assistance, attempt, Babb, Background, base, baseline, Baylor, begin, bind, Binomial, biological, biologically, biotechnology, BL, block, blocked, breakthrough, build, building, built, categorizing, category, cellular, central, chain, characterized, chemotherapeutic, chemotherapy, choice, chromosomal, chronically, circulating, clearance, clofarabine, code, College, colon, combined, commit, complementary, complex, complexed, concept, conducted, confirming, connect, consisting, consultation, consummation, continued, controlling, convert, Cornell, creating, culminating, cycle, dasatinib, death, debilitating, delayed, deliver, delivering, dependence, design, designation, designing, detected, detection, diffuse, disclose, discontinued, discovery, diseased, disorder, Distinguishing, distribute, DLBCL, dosed, downstream, drop, duration, elderly, eleven, eliminate, EMA, encountered, endpoint, epidermal, ERK, escalating, essential, estrogen, European, evaluate, eventually, evidence, exclusivity, exist, expansion, expectancy, experienced, expert, explanation, expression, extended, extracellular, face, facilitate, fact, factor, failed, fall, family, female, fewer, field, fight, figure, final, fixed, FL, flow, fludarabine, follicular, formal, fragile, frequently, gemtuzumab, genetic, genetically, Genta, Gleevec, great, growth, hallmark, head, Health, Hematology, hierarchy, highest, HIV, hope, hormonal, hormone, human, Ib, IBC, ideal, identical, imatinib, immature, importantly, improved, improvement, incidence, increasing, independence, independent, indirectly, induction, ineligible, infection, inflamed, inflammatory, inherent, inhibit, inhibiting, inhibitor, initiated, initiating, initiation, inserted, Institute, instrument, integral, intensive, intention, interest, interested, interesting, interior, interrupting, introduction, investigator, involving, Jersey, key, kill, kinase, lacking, large, Lattice, leading, learned, led, left, leptomeningeal, leukemic, level, life, likelihood, limiting, liposome, liver, low, lowest, lymph, machinery, making, male, malignancy, MALT, manage, marked, Mary, matching, mature, maximum, MCL, measure, measured, measurement, mechanism, Medical, meeting, member, membrane, milestone, MTD, multiple, mutated, National, neck, negative, NHL, nilotinib, Nonqualified, nucleotide, observable, observed, October, older, opportunity, optimal, order, organized, orphan, overcome, overexpressed, overlapping, partial, pathway, people, percent, percentage, perform, peripheral, pERK, phenotype, phosphate, phosphorothioate, Phosphorylated, physiologic, potentially, preoperative, presence, prevalence, prevented, prevention, principle, prioritizing, priority, proactive, proceed, processing, produced, production, profile, progesterone, programmed, progression, proliferation, proof, proposed, prostate, provision, pursuing, quoted, radiation, Randolph, rapid, rare, Ras, reach, reaching, real, rearrangement, receptor, recipe, red, reducing, regimen, regulating, relapse, relevant, remain, removed, replication, requested, requiring, resist, resistant, respond, resubmit, revise, Ribonucleic, ribose, Rituximab, RNA, routine, safe, safely, sample, Scott, September, serve, short, show, shut, signal, signaling, similarity, siRNA, site, situated, skin, Society, specifically, speed, stabilization, stabilized, standalone, statistically, stem, structural, submitted, sugar, suggested, suicide, supported, supporting, surface, surgery, switch, swollen, team, test, tested, therapeutic, therapeutically, thyroid, TNBC, today, tolerance, tolerated, tool, toxicity, traditional, transcribed, transcription, transfer, transform, transformative, transient, translating, translation, translocation, transplant, transport, transported, treating, triple, turned, turnover, type, typically, Unadjusted, unexpected, unfit, Union, Unit, unmet, unobservable, unstable, untreated, updated, utilize, variety, varying, Virginia, warranty, WBC, Weill, West, white, wide, work, yield
Filing tables
Filing exhibits
Related press release
Associated BPTH transcripts
BPTH similar filings
Filing view
External links
Exhibit 32
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Bio-Path Holdings, Inc. (the “Company”) for the quarter ended March 31, 2018 as filed with the Securities and Exchange Commission (the “Report”), I, Peter H. Nielsen, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Date: May 15, 2018 | By: | /s/ Peter H. Nielsen |
| Peter H. Nielsen | ||
| Chief Executive Officer | ||
| Chief Financial Officer |